| **Finerenone compared to placebo for Chronic Kidney Disease** |
| --- |
| Outcomes | **Anticipated absolute effects\*** (95% CI) | Relative effect(95% CI) | № of participants(studies) | Certainty of the evidence(GRADE) |
| **Risk with placebo** | **Risk with Finerenone** |
| decrease in eGFR | / | MD **2.44 lower**(2.82 lower to 2.05 lower) | - | 6090(4 RCTs) | ⨁⨁⨁◯Moderatea |
| mean UACR ratio to baseline | / | MD **0.3 lower**(0.32 lower to 0.28 lower) | - | 13096(5 RCTs) | ⨁⨁⨁◯Moderatea |
| decrease of ≥40% in eGFRfrom baseline | 148 per 1,000 | **125 per 1,000**(115 to 137) | **RR 0.85**(0.78 to 0.93) | 13452(3 RCTs) | ⨁⨁⨁◯Moderatea |
| cardiovascular events | 141 per 1,000 | **124 per 1,000**(113 to 134) | **RR 0.88**(0.80 to 0.95) | 13661(4 RCTs) | ⨁⨁⨁◯Moderatea |
| End-stage kidney disease | 29 per 1,000 | **23 per 1,000**(19 to 29) | **RR 0.80**(0.65 to 0.99) | 13026(2 RCTs) | ⨁⨁⨁◯Moderatea |
| change in serum potassium | / | MD **0.17 higher**(0.1 higher to 0.24 higher) | - | 13373(5 RCTs) | ⨁⨁⨁◯Moderatea |
| hyperkalemia | 68 per 1,000 | **138 per 1,000**(125 to 154) | **RR 2.03**(1.83 to 2.26) | 13435(3 RCTs) | ⨁⨁⨁⨁Higha, b |
| adverse events | 855 per 1,000 | **855 per 1,000**(838 to 863) | **RR 1.00**(0.98 to 1.01) | 13679(5 RCTs) | ⨁⨁⨁◯Moderatea |
| \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).**CI:** confidence interval; **MD:** mean difference; **RR:** risk ratio |

a. Risk of bias

b. Large effect